References: -
  1. Osuchowski MF, Winkler MS, Skirecki T, et al. The COVID-19 puzzle deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir Med. 2021;9(6):622–642.
  2. Venet F, Cour M, Rimmele T, et al. Longitudinal assessment of IFN-I activity and immune profile in critically ill COVID-19 patients with acute respiratory distress syndrome. Crit Care. 2021;25(1):140.
  3. Remy KE, Mazer M, Striker DA, et al. Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections. JCI Insight. 2020;5(17).
  4. NIH. COVID-19 treatment guidelines panel. coronavirus disease 2019 (COVID-19) treatment guidelines (2020). Available at: https://www. covid19treatmentguidelines.nih.gov/.
  5. Ni L, Ye F, Cheng ML, Feng Y, Deng YQ, Zhao H, et al. Detection of SARSCoV-2-Specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity (2020) 52(6):971–77.e3. doi: 10.1016/j.immuni.2020.04.023
  6. Ghizlane EA, Manal M, Abderrahim EK, Abdelilah E, Mohammed M, Rajae A, et al. Lymphopenia in covid-19: A single center retrospective study of 589 cases. Ann Med Surg (2021) 69:102816. doi: 10.1016/j.amsu.2021.102816
  7. Lee J, Park SS, Kim TY, Lee DG, Kim DW. Lymphopenia as a biological predictor of outcomes in COVID-19 patients: A nationwide cohort study. Cancers (Basel) (2021) 13(3):471. doi: 10.3390/cancers13030471
  8. Ramljak D, Vukoja M, Curlin M, Vukojevic K, Barbaric M, Glamoclija U, et al. Early response of CD8+ T cells in COVID-19 patients. J Pers Med (2021) 11 (12):1291. doi: 10.3390/jpm11121291
  9. He R, Lu Z, Zhang L, Fan T, Xiong R, Shen X, et al. The clinical course and its correlated immune status in COVID-19 pneumonia. J Clin Virol (2020) 127:104361. doi: 10.1016/j.jcv.2020.104361
  10. Chen Z, John Wherry E. T Cell responses in patients with COVID-19. Nat Rev Immunol (2020) 20(9):529–36. doi: 10.1038/s41577-020-0402-6
  11. Suryawanshi, P., Takbhate, B., Athavale, P., Jali, P., Memane, N., Mirza, S., Karandikar, M., Kakrani, A. L., Kanitkar, S., Gandham, N., Barthwal, M. S., Dole, S., Chaturvedi, S., Pawale, S., Tripathy, A., Bhawalkar, J. S., & Tripathy, S. (2023). Lymphopenia with Altered T Cell Subsets in Hospitalized COVID-19 Patients in Pune, India. Viral immunology36 (3), 163–175. https://doi.org/10.1089/vim.2022.0123
  12. Fathi N, Rezaei N. Lymphopenia in COVID-19: Therapeutic opportunities. Cell Biol Int (2020) 44(9):1792–7. doi: 10.1002/cbin.11403
  13. Schultheiß C, Paschold L, Simnica D, Mohme M, Willscher E, von Wenserski L, et al. Next-generation sequencing of T and b cell receptor repertoires from COVID-19 patients showed signatures associated with severity of disease. Immunity (2020) 53(2):442–55.e4. doi: 10.1016/j.immuni.2020.06.024
  14. Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin JB, Olsson A, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell (2020) 183(1):158–68.e14. doi: 10.1016/j.cell.2020.08.017
  15. Wilk AJ, Rustagi A, Zhao NQ, Roque J, Martı́nez-Colón GJ, McKechnie JL, et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat Med (2020) 26(7):1070–6. doi: 10.1038/s41591-020-0944-y
  16. Li S, Zhang Y, Guan Z, Li H, Ye M, Chen X, et al. SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation. Signal Transduct Target Ther (2020) 5(1):235. doi: 10.1038/s41392-020-00334-0
  17. Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci (2020) 57(6):389–99. doi: 10.1080/10408363.2020.1770685
  18. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest (2020) 130(5):2620–9. doi: 10.1172/JCI137244
  19. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med (2020) 382 (18):1708–20. doi: 10.1056/NEJMoa2002032
  20. Zhang S, Asquith B, Szydlo R, Tregoning JS, Pollock KM, et al. Peripheral T cell lymphopenia in COVID-19: Potential mechanisms and impact. Immunother Adv (2021) 1(1):ltab015. doi: 10.1093/immadv/ltab015
  21. Bao J, Li C, Zhang K, Kang H, Chen W, Gu B. Comparative analysis of laboratory indexes of severe and non-severe patients infected with COVID-19. Clin Chim Acta (2020) 509:180–94. doi: 10.1016/j.cca.2020.06.009
  22. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in wuhan, China. Clin Infect Dis (2020) 71(15):762–8. doi: 10.1093/cid/ciaa248
  23. Kalfaoglu B, Almeida-Santos J, Tye C.A, Satou Y, Ono M. T-Cell hyperactivation and paralysis in severe COVID-19 infection revealed by singlecell analysis. Front Immunol (2020) 11. doi: 10.3389/fimmu.2020.589380
  24. Zingaropoli MA, Perri V, Pasculli P, Cogliati Dezza F, Nijhawan P, Savelloni G, et al. Major reduction of NKT cells in patients with severe COVID-19 pneumonia. Clin Immunol (2021) 222:108630. doi: 10.1016/j.clim.2020.108630
  25. Kreutmair S, Unger S, Núñez NG, Ingelfinger F, Alberti C, De Feo D, et al. Distinct immunological signatures discriminate severe COVID-19 from non- SARS-CoV-2-driven critical pneumonia. Immunity (2021) 54(7):1578–93.e5. doi: 10.1016/j.immuni.2022.01.015
  26. Jouan Y, Guillon A, Gonzalez L, Perez Y, Boisseau C, Ehrmann S, et al. Phenotypical and functional alteration of unconventional T cells in severe COVID-19 patients. J Exp Med (2020) 217(12):e20200872.
  27. Gong F, Dai Y, Zheng T, Cheng L, Zhao D, Wang H, et al. Peripheral CD4+ T cell subsets and antibody response in COVID-19 convalescent individuals. J Clin Invest (2020) 130(12):6588–99. doi: 10.1172/JCI141054
  28. Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin JB, Olsson A, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell (2020) 183(1):158–68.e14. doi: 10.1016/j.cell.2020.08.017
  29. Kundu R, Narean JS, Wang L, Fenn J, Pillay T, Fernandez ND, et al. Crossreactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts. Nat Commun (2022) 13(1):80 doi: 10.1038/s41467-021-27674-x.
  30. Kared H, Redd AD, Bloch EM, Bonny TS, Sumatoh H, Kairi F, et al. SARSCoV- 2-specific CD8+ T cell responses in convalescent COVID-19 individuals. J Clin Invest (2021) 131(5):e145476:e145476. doi: 10.1172/JCI145476
  31. Cohen KW, Linderman S.L, Moodie Z, Czartoski J, Lai L, Mantus G, et al. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory b and T cells. medRxiv (2021) 2(7):100354. doi: 10.1016/j.xcrm.2021.10035
  32. Cao W-C, Liu W, Zhang P-H, Zhang F, Richardus JH. Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med (2007) 357 (11):1162–3. doi: 10.1056/NEJMc070348
  33. Ng O-W, Chia A, Tan AT, Jadi RS, Leong HN, Bertoletti A, et al. Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection. Vaccine (2016) 34(17):2008–14. doi: 10.1016/j.vaccine.2016.02.063
  34. MacLeod MKL, Kappler JW, Marrack P. Memory CD4 T cells: generation, reactivation and re-assignment. Immunology (2010) 130(1):10–5. doi: 10.1111/j.1365-2567.2010.03260.x
  35. Farber DL, Yudanin NA, Restifo NP. Human memory T cells: generation, compartmentalization and homeostasis. Nat Rev Immunol (2014) 14(1):24–35. doi:10.1038/nri3567
  36. Tian Y, Babor M, Lane J, Schulten V, Patil VS, Seumois G, et al. Unique phenotypes and clonal expansions of human CD4 effector memory T cells re-expressing CD45RA. Nat Commun (2017) 8(1):1473. doi: 10.1038/s41467-017-01728-5
  37. Graham N, Eisenhauer P, Diehl SA, Pierce KK, Whitehead SS, Durbin AP, et al. Rapid induction and maintenance of virus-specific CD8(+) T(EMRA) and CD4(+) T(EM) cells following protective vaccination against dengue virus challenge in humans. Front Immunol (2020) 11:479. doi: 10.3389/ fimmu.2020.00479
  38. Govender M, Hopkins FR, Göransson R, Svanberg C, Shankar EM, Hjorth M, Nilsdotter-Augustinsson Å, Sjöwall J, Nyström S and Larsson M (2022) T cell perturbations persist for at least 6 months following hospitalization for COVID-19. Front. Immunol. 13:931039. doi:10.3389/fimmu.2022.931039
  39. Bonifacius A, Tischer-Zimmermann S, Dragon AC, Gussarow D, Vogel A, Krettek U, et al. COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses. Immunity (2021) 54(2):340–54.e6. doi: 10.1016/j.immuni.2021.01.008
  40. Zenarruzabeitia O, Astarloa-Pando G, Terrén I, Orrantia A, Pérez-Garay R, Seijas-Betolaza I, et al. T Cell Activation, Highly armed cytotoxic cells and a shift in monocytes CD300 receptors expression is characteristic of patients with severe COVID-19. Front Immunol (2021) 12. doi: 10.3389/fimmu.2021.655934
  41. Le Bert N, Tan A.T, Kunasegaran K, Tham C.Y.L, Hafezi M, Chia A, et al. SARS-cov-2-specific t cell immunity in cases of covid-19 and sars, and uninfected controls. Nature (2020) 584(7821):457–62. doi: 10.1038/s41586-020-2550-z
  42. Björkander S, Du L, Zuo F, Ekström S, Wang Y, Wan H, et al. SARS-CoV-2- specific b- and T-cell immunity in a population-based study of young Swedish adults. J Allergy Clin Immunol (2022) 149(1):65–75.e8. doi: 10.1016/j.jaci.2021.10.014
  43. Kalfaoglu B, Almeida-Santos J, Tye CA, Satou Y, Ono M. T-Cell dysregulation in COVID-19. Biochem Biophys Res Commun (2021) 538:204–10. doi: 10.1016/j.bbrc.2020.10.079
  44. Zuo J, DowellA.C, Pearce H, Verma K, Long HM, Begum J, et al. Robust SARSCoV- 2-specificT cell immunity is maintained at 6months following primary infection. Nat Immunol (2021) 22(5):620–6. doi: 10.1038/s41590-021-00902-8
  45. Long QX, Li Q.L, Deng Q, Yuan H.J, J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med (2020) 26(8):1200– 4. doi: 10.1038/s41591-020-0965-6
  46. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. Rapid decay of anti–SARS-CoV-2 antibodies in persons with mild covid-19. N Engl J Med (2020) 383(11):1085–7. doi: 10.1056/ NEJMc2025179
  47. Sherina N, Piralla A, Du L, Wan H, Kumagai-Braesch M, réll J, et al. Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6–8 months after the infection. Med (2021) 2(3):281–95.e4.doi: 10.1016/j.medj.2021.02.001
  48. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science (2021) 371(6529):eabf4063. doi: 10.1126/science.abf4063
  49. Muecksch F, Weisblum Y, Barnes C.O, Schmidt F, Schaefer-Babajew D, Wang Z, et al. Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity (2021) 54 (8):1853–68.e7. doi: 10.1016/j.immuni.2021.07.008
  50. Aleem A, Akbar Samad AB, Slenker AK. Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19), in StatPearls. Treasure Island FL: StatPearls Publishing, Copyright © 2022, StatPearls Publishing LLC (2022).
  51. Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA (2020) 324(6):603–5. doi: 10.1001/jama.2020.12603
  52. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet (2021) 397(10270):220–32. doi: 10.1016/S0140-6736(20)32656-8
  53. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med (2022) 28:583–90. doi: 10.1038/s41591-022-01689-3